IgA Nephropathy Treatment (IgAN) Market Set to hit Strategic Investment by United States & APAC

DataM Intelligence has published its latest research report, "IgA Nephropathy Treatment Market Size 2026." The report provides comprehensive analysis of market dynamics, including regional growth patterns, segment-wise performance, CAGR forecasts, competitive positioning, and revenue trends across key industry participants. It also examines the major factors influencing market expansion, emerging business opportunities, and strategic developments. Designed to support informed business planning, the study delivers a clear assessment of market value, volume, and future growth prospects within the global IgA Nephropathy Treatment market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/iga-nephropathy-treatment-market?kb

United States: Recent Industry Developments

✅ May 2026: Otsuka Pharmaceutical presented positive Phase 3 VISIONARY interim data showing VOYXACT® (sibeprenlimab) preserved kidney function over 12 months in patients with IgA nephropathy, supporting its long-term disease-modifying potential.

✅ April 2026: Travere Therapeutics continued expanding commercialization of FILSPARI® (sparsentan) across the U.S. following increased physician adoption for IgA nephropathy treatment.

✅ March 2026: Novartis advanced regulatory activities for Fabhalta® (iptacopan) using Phase 3 APPLAUSE-IgAN data supporting long-term kidney function preservation.

✅ January 2026: Vera Therapeutics received U.S. FDA Priority Review for its Biologics License Application for atacicept in adults with IgA nephropathy, with a PDUFA target date of July 7, 2026.

Ready to get in the IgA Nephropathy Treatment Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/iga-nephropathy-treatment-market?kb

List of Key Players 2026:

Travere Therapeutics, Inc., Calliditas Therapeutics AB, STADA Arzneimittel, Everest Medicines, Viatris Inc., and Novartis AG, among others., Vertex Pharmaceuticals Incorporated.

Emerging Companies 2026:

Vertex Pharmaceuticals Incorporated, RemeGen, Wuxi BioCity, F. Hoffmann-La Roche Ltd/Ionis Pharmaceuticals, Vera Therapeutics, Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited., and Wuhan Createrna Science and Technology Co.,Ltd

Latest FDA approvals by IgA Nephropathy Treatment 2026:

VOYXACT (sibeprenlimab-szsi) received FDA accelerated approval in late 2025 for adults with primary IgA nephropathy at risk of progression, and it remained the key recent approval shaping the 2026 landscape.

By the end of 2025, public kidney-disease coverage noted six FDA-approved treatment options for rare kidney disease settings that include IgAN-focused therapies such as VOYXACT, FABHALTA, FILSPARI, TARPEYO, and VANRAFIA.

Growth Forecast Projected 2026:

The Global IgA Nephropathy Treatment Market is projected to witness significant growth during the forecast period from 2026 to 2033. The market maintained steady momentum in 2025, and increasing strategic investments, technological advancements, and expansion initiatives by leading companies are expected to accelerate market growth throughout the forecast period.

Key Developments 2026:

In June 2026, Vertex Pharmaceuticals announced that the U.S. FDA accepted its Biologics License Application (BLA) for povetacicept for the treatment of IgA nephropathy, with a PDUFA target action date of November 30, 2026.

In June 2026, Vera Therapeutics aligned with the U.S. FDA on an accelerated regulatory pathway for atacicept, supporting potential full approval for adults with IgA nephropathy following its July 2026 PDUFA date.

In June 2026, Otsuka Pharmaceutical presented positive interim Phase 3 VISIONARY data showing that VOYXACT® (sibeprenlimab-szsi) preserved kidney function over 12 months in adults with IgA nephropathy.

In June 2026, Viatris announced positive top-line Phase 3 results for VR-205 (targeted-release budesonide) in Japanese adults with primary IgA nephropathy, supporting plans for a New Drug Application submission in Japan by the end of 2026.

How Our Market Research Process Works:

The global IgA Nephropathy Treatment Market research report is built on a robust blend of primary and secondary research methodologies. The study provides detailed analysis of key market influences, including regulatory frameworks, shifting industry dynamics, competitive landscapes, and historical market performance. It further examines technological progress, emerging innovations, and developments across adjacent sectors. Additionally, the report evaluates growth potential, market uncertainties, operational challenges, and emerging opportunities that are expected to shape the future trajectory of the global IgA Nephropathy Treatment market.

Recent Mergers & Acquisitions (M & A) 2026:

• June 2026: Travere Therapeutics entered an exclusive licensing agreement with Everest Medicines to develop and commercialize civorebrutinib for rare kidney diseases, expanding its nephrology portfolio

Request Strategic Market Customization: https://datamintelligence.com/customize/iga-nephropathy-treatment-market?kb

Japan: Recent Industry Developments

✅ May 2026: Otsuka Pharmaceutical highlighted positive Phase 3 VISIONARY interim results demonstrating sustained kidney function preservation with VOYXACT® in IgA nephropathy patients.

✅ March 2026: Otsuka Pharmaceutical continued global regulatory submissions to expand VOYXACT® approvals based on ongoing Phase 3 clinical evidence for IgA nephropathy.

✅ February 2026: Otsuka Pharmaceutical advanced post-approval commercialization initiatives in Japan and global markets to strengthen access to targeted IgA nephropathy therapies.

✅ January 2026: Otsuka Pharmaceutical progressed long-term clinical evaluation of VOYXACT®, generating additional evidence to support traditional regulatory approvals worldwide.

Major Focused Key Segmentations 2026:

By Disease Type: Primary IgA Nephropathy and Secondary IgA Nephropathy

By Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Dual Endothelin Angiotensin Receptor Antagonists (DEARAs), SGLT2 Inhibitors, Corticosteroids, Endothelin Receptor Antagonists (ETA), and Others

By Gender: Male and Female

Latest Investments in the IgA Nephropathy Treatment Market (2025-2026)

• July 2026: Vera Therapeutics strengthened its commercial investment following the FDA approval of Trutakna, expanding manufacturing, commercialization, and patient access programs for IgA nephropathy.

• November 2025: Otsuka Pharmaceutical invested in the commercial launch of Voyxact (sibeprenlimab) after receiving FDA accelerated approval for IgA nephropathy, expanding its nephrology portfolio.

• 2025: Novartis continued significant investment in Fabhalta (iptacopan) through post-approval studies and global commercialization following its FDA approval for IgA nephropathy.

• 2025: Novartis increased investment in Vanrafia (atrasentan) commercialization after FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy.

• 2025-2026: Vertex Pharmaceuticals continued investing in late-stage development of its dual BAFF/APRIL inhibitor for IgA nephropathy ahead of an anticipated regulatory decision.

• 2025-2026: Roche and Ionis Pharmaceuticals expanded investment in Phase 2/3 clinical development of Sefaxersen, targeting complement factor B for IgA nephropathy treatment.

• 2025-2026: Chinook Therapeutics (Novartis) continued investment in clinical development of zigakibart (BION-1301), an investigational APRIL inhibitor for IgA nephropathy.

Regional Growth Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

We Provide Benefits of the Report:

Chapter 1: Establishes the report framework by outlining market scope, key segments by region, product type, and application. It provides a comprehensive overview of current market size, growth outlook, and projected industry development across short-, medium-, and long-term horizons.

Chapter 2: Highlights the most influential market findings, examining the major trends, opportunities, and forces driving industry transformation and future growth.

Chapter 3: Delivers an in-depth assessment of the competitive environment, including market share analysis, strategic developments, partnerships, and mergers & acquisitions influencing industry dynamics.

Chapter 4: Profiles leading market participants with detailed insights into financial performance, product offerings, business strategies, profitability, and significant corporate developments.

Chapters 5 & 6: Provide comprehensive revenue analysis at regional and country levels, identifying market size, growth trends, investment hotspots, and emerging expansion opportunities worldwide.

Chapter 7: Examines the market by product category, uncovering segment-level performance trends and highlighting promising areas for future growth and investment.

Chapter 8: Evaluates the market by application, analyzing demand patterns across end-use industries and identifying sectors expected to generate substantial growth opportunities.

Chapter 9: Offers a detailed overview of the industry value chain, covering upstream suppliers, downstream consumers, and key processes that influence market development.

Chapter 10: Concludes with a strategic summary of the report's most important findings, market opportunities, and actionable insights shaping the industry's future direction.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=iga-nephropathy-treatment-market?kb

FAQ

Q1: What is the current valuation of the IgA Nephropathy Treatment Market?

A: The IgA Nephropathy Treatment Market was valued at US$ 525.43 million in 2025 and is anticipated to reach US$ 2674.01 million by 2033, reflecting strong growth potential across key industry segments.

Q2: What is the projected growth rate of the IgA Nephropathy Treatment Market?

A: The IgA Nephropathy Treatment Market is expected to expand at a CAGR of 22.41 % from 2026 to 2033, driven by increasing demand, evolving consumer preferences, and expanding application areas.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

IgAN Treatment 2026: Latest Approvals and Clinical Pipeline

The 2026 IgAN trial landscape is active, with recent reviews highlighting ongoing work in complement inhibition, endothelin receptor antagonism, and B-cell/plasma-cell targeting.

Public trial trackers in 2026 list studies such as VISIONARY, RAINIER, JUNIPER, IMAGINATION, and PREVAIL, showing broad late-stage development across multiple mechanisms.

June 2026 pipeline coverage says the IgAN clinical-trial space has intensified to 25+ companies and 30+ pipeline drugs, underscoring strong development momentum.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.